

January 07, 2016

Adam Myers
SSCI
3065 Kent Avenue
West Lafayette, IN 47909

Dear Mr Myers:

Testing for Study #151142-203, entitled "A NON-GLP ANTIMICROBIAL PRESERVATIVES EFFECTIVENESS EVALUATION OF SIX PRODUCTS WHEN CHALLENGED WITH FOUR MICROORGANISM SPECIES BASED ON EUROPEAN PHARMACOPOEIA METHOD 5.1.3." is complete. A Preservative Effectiveness Evaluation of six test products was conducted with samples taken at 24 hours, 7 days, 14 days, and 28 days following inoculation, for the two bacterial species (*Pseudomonas aeruginosa* [ATCC #9027] and *Staphylococcus aureus* [ATCC #6538]). Samples were taken at 14 days, 21 days, and 28 days following inoculation with the fungal species, (*Aspergillus brasiliensis* [ATCC #16404] and *Candida albicans* [ATCC #10231]). Testing was based upon the methods outlined in European Pharmacopoeia 7.0, 5.1.3., *Efficacy Of Antimicrobial Preservation*, 01/2011:50103 and details are enclosed as Study Protocol #151142-203 (Addendum 1). Three deviations from Study Protocol #151142-203 occurred and one deviation from BioScience Standard Operating Procedures occurred during the course of this evaluation and are documented as Deviation 01, 02, 03, 04 and included in Addendum 1.

All six test products met the acceptance criteria outlined in the European Pharmacopoeia 7.0, 5.1.3. *Efficacy Of Antimicrobial Preservation*, 01/2011:50103. Acceptance Criteria, Table 5.1.3.1, *Parenteral preparations, eye preparations, intrauterine preparations and intramammary preparations*: Criteria A for bacteria is a 3 log₁₀ reduction following 24 hours of exposure to the test product with no Colony Forming Units (CFU) recovered after 28 days of exposure to the test product and the Criteria A for fungi is a 2 log₁₀ reduction following 7 days of exposure to the test product with no increase in the number of viable microorganisms compared to the previous reading after 28 days of exposure to the test product. All results are included in Addendum 2.

This final report is amended to reflect the changes to the Initial Population (CFU/1.0 mL of product), the Log₁₀ Reduction, and the Percent Reduction for the fungal species due to the varying volumes of product employed for the fungal evaluation. Tables 1, 2, 7, 8, 13, and 14 were updated to reflect the changes to the Initial Population (CFU/1.0 mL of product), the Log₁₀ Reduction, and the Percent Reduction of *Aspergillus brasiliensis* (ATCC #16404) and *Candida albicans* (ATCC #10231). The data reported for Test Product #2 and Test Product #6 for *Candida albicans* (ATCC #10231) remained as originally reported in Addendum 2. All raw data is included in Addendum 3

We appreciate the opportunity to assist you and look forward to serving you in the near future with any of your testing needs. Please contact our Sales and Marketing Department at (877) 858-2754, toll free.

Sincerely,

A handwritten signature in black ink, appearing to read 'Dan Dragotoiu'.

Dan Dragotoiu
Study Director: In-Vitro Laboratory

LETTER FINAL REPORT #151142-203.01
BIOSCIENCE LABORATORIES, INC.
Page 1 of 1

CONFIDENTIAL

PROL0337789

DOCKET
ALARM

Find authenticated court documents without watermarks at docketalarm.com.

ADDENDUM 1

Protocol #151142-203
Protocol Deviation Recording Forms (Form No. 99-QA-004)

CONFIDENTIAL

PROL0337790



Find authenticated court documents without watermarks at docketalarm.com.



November 23, 2015

PROTOCOL #151142-203

**A NON-GLP ANTIMICROBIAL PRESERVATIVES EFFECTIVENESS EVALUATION OF SIX
PRODUCTS WHEN CHALLENGED WITH FOUR MICROORGANISM SPECIES BASED ON
EUROPEAN PHARMAOPOEIA METHOD 5.1.3.**

Prepared for:

SSCI (SPONSOR)
3065 Kent Avenue
West Lafayette, IN 47909

Prepared by:

BIOSCIENCE LABORATORIES, INC. (TESTING FACILITY)
1755 South 19th Avenue
Bozeman, Montana 59718
(406) 587-5735

PROTOCOL #151142-203
Page 1 of 11
BIOSCIENCE LABORATORIES, INC.

CONFIDENTIAL

PROL0337791

CONFIDENTIAL

This Document has been copyrighted by BioScience Laboratories, Inc., and is considered confidential between BioScience Laboratories, Inc. (Testing Facility) and SSCI (Sponsor). This document is not to be shown, given to, or used by anyone except SSCI without written permission from BioScience Laboratories, Inc. Permission to release the Protocol and Study Results to the United States Food and Drug Administration (FDA) is explicitly granted.


PROTOCOL #151142-203
Page 2 of 11
BIOSCIENCE LABORATORIES, INC.

CONFIDENTIAL

PROL0337792



TABLE OF CONTENTS



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.